Trials / Completed
CompletedNCT00000298
Buprenorphine Combination Tablet Feasibility - 1
Buprenorphine Combination Tablet Feasibility
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (planned)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 21 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine target dose range of buprenorphine/naloxone combination tablet that provides therapeutic response in opiate addicts with low to moderate dependence, and to identify appropriate initial induction dose in opiate addicts with low to moderate dependence."
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Buprenorphine/naloxone |
Timeline
- Start date
- 1995-08-01
- First posted
- 1999-09-21
- Last updated
- 2005-08-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00000298. Inclusion in this directory is not an endorsement.